The development of GTAP-USL economic model marks another step forward in our efforts to make the GTAP more realistic and a better predictor of the real-world effects of trade policies or trade shocks. It’s critical to build models that provide a better understanding of how policies impact people, families, racial groups, gender, cities and regions. There is still more work to be done.
China’s trade surplus has crossed a dangerous threshold. In 2025, it exceeded $1 trillion for the first time, surpassing the previous record of $993 billion.
U.S. drugmakers are rapidly shifting the front end of America’s pharmaceutical ecosystem (e.g. discovery, early-stage-development, and the IP engine) to China through a surge of licensing deals and cross-border partnerships.
The United States is facing a new form of strategic dependence: Chinese-linked firms are reentering critical American industries through influence and control rather than visible ownership.
The current cost-of-living crisis – defined by the soaring cost of essential services – is not the result of excessive consumer demand or short-term inflation shocks. It is the product of decades of trade and industrial policy choices that weakened middle-class wage growth.
CPA’s submission, “Ensuring U.S. Sovereignty in North American Trade,” concludes that the current trilateral USMCA framework binds two vastly different economies to one unenforceable system—with each reliant on the far larger U.S. consumer market.
The report, titled “Section 232 Steel Tariffs are Necessary for National Security,” highlights how the Trump administration’s Section 232 tariffs have revitalized American manufacturing, created jobs, and strengthened national security.
KEY POINTS Beef prices are at record highs—not because of U.S. ranchers or tariffs, but because dependence on foreign imports and meatpacker consolidation have distorted
The report, titled “America’s Chip-for-Chip Tariff Policy: The Urgent Fight to Reclaim Industrial Independence Before It’s Too Late,” finds that the United States now produces only 10 percent of the world’s chips—and almost none of the most advanced ones—while China has captured the majority of global capacity for legacy chips, the mature semiconductors essential to cars, medical devices, and industrial equipment.
Titled “The New Biotech Cold War: The U.S. Medicine Can’t Afford to Fall Behind China,” the report shows how U.S. biotech – long a pillar of national strength – no longer has a guaranteed edge globally.
